Biolase (NSDQ:BIOL) said earlier this month that CEO Jeffery Nugent has resigned from both his position as CEO and the board of directors, effective July 12, to be replaced by Harold Flynn. Irvine, Calif.-based Biolase picked up Flynn, the former president of Zimmer Dental (NYSE:ZMH), in May to replace Nugent, who the company said had stepped in to […]
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Imagine a future in which a software program, tapped into a database containing every electronic medical record in the country, helps guide your every interaction with your doctor.
In a recent interview with Nuance’s Carina Edwards, she took MassDevice through a tour of the shift from speech recognition to speech understanding, how artificial intelligence will revolutionize medical coding and what the Jeopardy-winning Watson supercomputer might be able to do for medicine.
Shares of St. Jude Medical (NYSE:STJ) clawed back some of the value lost yesterday in what 1 waggish analyst termed a “Greek tragedy.”
STJ shares closed down 3.3% yesterday at $39.96 when the company revealed a $56 million writedown after a Greek distributor failed to pay up for an estimated 2 years worth of sales.
MASSDEVICE ON CALL — Newer generations of artificial hips may not be as good as their predecessors, according to research funded by the FDA.
Modern hip replacement devices using metal-on-metal joints or ceramic-on-ceramic joints may wear out faster than metal-on-polyethylene or ceramic-on-polyethylene models.
In a comparative study examining the records of more than 3,000 patients and 3,400 hips, the overall results found no advantage in the more expensive, newer artificial hips, but did see a higher rate of revision surgery in some of the results.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Nuance Communications (NSDQ:NUAN) CEO Paul Ricci allegedly tried to lay $5 million bribes before a trio of executives at competitor Vlingo Inc. in an effort to force through a below-market-price buyout, according to a lawsuit filed by Vlingo against its Massachusetts peer.
Covidien Plc. (NYSE:COV) announced a new agreement for a five year $1.5 billion senior unsecured revolving credit facility, secured through subsidiary Covidien International Finance S.A.
The new agreement replaces a prior five-year senior credit facility that was slated to mature in April 2012, and the funds will be allocated for general corporate purposes, including working capital and capital expenditures.
If Nuance Communications (NSDQ:NUAN) had its way, medical transcription would be a two-way conversation between man and machine.
The company is looking to transform the transcription process into a back-and-forth between the physician and an intelligent software program that prompts for details and suggests potential courses of treatment based on a more holistic view of the patient story.